SEATTLE, June 10, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S Intravenous Solution Market is estimated to be valued at US$ 2,811.3 million in 2021 and is expected to exhibit a CAGR of 6.1% during the forecast period (2021-2028).
Key Trends and Analysis of the U.S Intravenous Solution Market:
The increasing number of product launches is expected to drive the growth of U.S intravenous solution market. For instance, in June 2019, Eurolife Healthcare, a manufacturer and distributor of specialty infusion & pharmaceuticals, launched two intravenous IV products Discport and Lifeport in the Indian drug market. The product is considered as “Smart intravenous infusion” with innovative technology that reduces the risk of infections.
The increasing number of inorganic growth strategies such as collaborations and acquisitions is expected to contribute to the growth of the U.S intravenous solution. For instance, , in April 2015, Baxter International Inc. and France-based Laboratoire Aguettant SAS entered into a licensing and distribution agreement for trace elements, which are essential micronutrients used in parenteral nutrition (PN) therapy.
Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/3400
Major Key players are expanding their business in the market through inorganic growth strategies such as acquisition. For instance, in August 2019, B. Braun Medical Inc. and Steward Health Care entered into purchasing agreement for seven years. Under this agreement, Steward Health Care will work with B. Braun Group of Companies till 2026 in the U.S. in order to procure IV solutions and to improve patient care and reduce the costs of the intravenous solutions.
The increasing incidence of traumatic brain injury is expected to drive the hypertonic solution sub-segment growth in the U.S intravenous solution market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), there were around 2.8 million traumatic brain injury-related emergency department visits, hospitalizations, and deaths in the U.S. in 2013.
Key Market Takeaways:
The Dextran segment is expected to be the largest share in U.S intravenous solution market to exhibit a CAGR of 6.5% during the forecast period (2021-2028), the increasing incidence of hypovolemia is expected to contribute to the growth of the dextran segment. For instance, according to National Center for Biotechnology Information, June 2019 report, the annual incidence of shock for any etiology is 0.3 to 0.7 per 1,000, with hemorrhagic shock being most common in the intensive care unit in the U.S.
Increasing investment by the major key players for the expansion of manufacturing units is expected to drive the U.S intravenous solution market. For instance, in May 2019, B. Braun Medical invested US$ 1 billion for construction of new facilities and for expansion of existing facilities that are engaged in producing and distribution of IV solutions.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3400
Key players operating in the U.S intravenous solution market are B. Braun Melsungen AG., Baxter International Inc., Fresenius Kabi USA, LLC, Grifols, S.A., JW Life Science, Amanta Healthcare, Salius Pharma Private Limited, Axa Parenterals Ltd., Vifor Pharma Management Ltd., Icu Medical, Inc., and Pfizer Inc.
Market Segmentation:
- U.S Intravenous Solution Market, By Solution Type:
- Saline
- Normal Saline (0.9% NaCl)
- Hypertonic saline
- Dextran
- D5W (5% dextrose in water)
- Analog Hypertonic Saline
- Lactated Ringer’s
- Amino Acid
- Vitamins & Minerals
- Heparin and trace elements
- Mixed Solutions
- Saline
- U.S Intravenous Solution Market, By Packaging Type:
- Ampules
- Vials
- Cartridges
- Bottles
- Bags
- Large Volume Bags (greater than 250ml)
- Small Volume Bags (less than 250ml)
- U.S Intravenous Solution Market, By Indication:
- Oncology
- Post-Operative Care
- General Medicine
- Burn Management
- Pulmonary Disorders
- Cardiovascular Diseases
- Others
- U.S Intravenous Solution Market, By End User:
- Hospitals
- Clinics
- Ambulatory Surgery Centres
- Home care Settings
- Others
Related Market Intelligence Reports:
Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market, By Type (IgG, IgA, and IgM), By Disease Indication (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CLL), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Urea Cycle Disorders Treatment Market, by Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others (Low Protein Diet, Carglumic acid, etc.), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase, and NAGS – N-acetylglutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read more: https://www.coherentmarketinsights.com/market-insight/urea-cycle-disorder-treatment-market-4441
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.